CRON
Cronos Group Inc.
CRON's fundamentals are strong: revenue grew 56% and its operating margin went from −16% to 3.4%. At 21x earnings, it's trading above its usual 18x. Analysts expect that strong growth to continue.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CRON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
CRON's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CRON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $0.62 | -82% |
| Forward | 17x | $3.41 | — |
| Fair | 18x | $2.82 | -17% |
| Current | 21x | $3.41 | — |
| Expensive | 40x | $6.32 | +85% |
Historical ranges are pointers, not guarantees.
CRON's PE is in its fair range at 21x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CRON Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
CRON has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CRON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.20 | +25% |
| Q3 2026 | $0.16 | +45% |
| Q2 2026 | $0.19 | +217% |
| Q1 2026 | $0.00 | -100% |
| Q4 2025 | -$0.02 | -118% |
| Q3 2025 | $0.11 | +$0.24 |
| Q2 2025 | $0.06 | +$0.21 |
| Q1 2025 | $0.14 | +$0.29 |
| Q4 2024 | $0.11 | +$0.30 |
CRON has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CRON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $63.5M | +75% |
| Q2 2026 | $53M | +58% |
| Q1 2026 | $45.2M | +40% |
| Q4 2025 | $44.5M | +47% |
| Q3 2025 | $36.3M | +6.1% |
| Q2 2025 | $33.5M | +21% |
| Q1 2025 | $32.3M | +28% |
| Q4 2024 | $30.3M | +27% |
CRON's revenue has grown year over year for 13 quarters in a row: $63M last quarter, up 75% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +16 points |
| Q2 2026 | 14% | +30 points |
| Q1 2026 | -4% | +8.6 points |
| Q4 2025 | -17% | +21 points |
| Q3 2025 | -1.4% | +97 points |
| Q2 2025 | -16% | +40 points |
| Q1 2025 | -13% | +51 points |
| Q4 2024 | -38% | +53 points |
CRON has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CRON on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CRON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.4M | +176% |
| Q2 2026 | $22.3M | +$23.3M |
| Q1 2026 | $9M | +$26.4M |
| Q4 2025 | $9.7M | +132% |
| Q3 2025 | $8.8M | +71% |
| Q2 2025 | -$1M | -200% |
| Q1 2025 | -$17.4M | -$13.4M |
| Q4 2024 | $4.2M | -73% |
CRON's free cash flow has turned positive again: $65M over the past year, against −$5M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CRON on cash flow, with more consistent year-over-year improvement.
CRON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -4.3M shares |
| 1 year | -3.7% | -14.3M shares |
| 3 years | -2.7% | -10.4M shares |
| 5 years | -1.3% | -4.9M shares |
| Available history | +8.1% | +27.9M shares |
CRON has 371M diluted shares, down 3.7% from a year ago, with $47M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $9.4M |
| Q2 2026 | $16.1M |
| Q1 2026 | $16.7M |
| Q4 2025 | $4.3M |
| Q3 2025 | $1.9M |
CRON spent $47M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CRON on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CRON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -27.0x | Net Cash |
| Q2 2026 | -82.1x | Net Cash |
CRON has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CRON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 62.5 | Neutral |
CRON's weekly RSI is 61 (neutral) and its Stochastic is 62 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CRON PE vs Healthcare Sector
| Metric | CRON | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 54 | 29 | 25 pts above |
CRON is trading at 21x earnings, a 18% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CRON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.33 | 2.4% above |
| 20 week MA | $3.17 | 7.6% above |
| 50 week MA | $2.87 | 19% above |
| 100 week MA | $2.50 | 36% above |
| 200 week MA | $2.31 | 48% above |
CRON has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CRON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.88 | $7.48 | +8.7% |
| 2021 | $7.48 | $4.26 | -43% |
| 2022 | $4.26 | $2.54 | -40% |
| 2023 | $2.54 | $2.09 | -18% |
| 2024 | $2.09 | $1.98 | -5.3% |
| 2025 | $1.98 | $2.66 | +34% |
| 2026 YTD | $2.66 | $3.41 | +28% |
CRON has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.